Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: An EORTC phase III study (10863)

L. Beex, Carsten Rose, H. Mouridsen, J. Jassem, M. Nooij, J. Estape, R. Paridaens, M. Piccart, T. Gorlia, S. Lardenoije, L. Baila

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: An EORTC phase III study (10863)'. Together they form a unique fingerprint.

Medicine and Dentistry

Biochemistry, Genetics and Molecular Biology

Pharmacology, Toxicology and Pharmaceutical Science